On January 6, 2021 Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, reported that it has initiated the submission of a New Drug Application (NDA) to the Health Sciences Authority (HSA) of Singapore for sacituzumab govitecan-hziy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease (Press release, Everest Medicines, JAN 6, 2021, View Source [SID1234573591]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Breast Cancer is Singapore’s number one leading cause of cancer death in women and TNBC accounts for 15-20% of all breast cancer in Singapore. This milestone marks the first of a series of planned NDA submissions for sacituzumab govitecan-hziy in Everest’s licensed territory, which also includes Greater China, South Korea, and certain additional Southeast Asian countries/regions," said Yang Shi, Chief Medical Officer for Oncology at Everest Medicines. "We look forward to making progress towards approval of sacituzumab govitecan-hziy in Singapore as we simultaneously advance our clinical development and regulatory programs in other parts of the territory in an effort to make this innovative treatment available to patients with this devastating disease across a broad range of emerging Asia Pacific."
"We are excited to achieve this important submission, which supports our larger business strategy to build a strong commercial presence in international markets in and outside of China as we work to connect and accelerate global pharmaceutical innovation for patients in the Asia Pacific region," said Kerry Blanchard, MD, PhD, CEO of Everest Medicines.
About Sacituzumab Govitecan-Hziy
Sacituzumab govitecan-hziy is a first-in-class, antibody-drug conjugate (ADC) directed at TROP-2, a membrane antigen that is over-expressed in many common epithelial cancers. Sacituzumab govitecan-hziy was granted accelerated approval by the U.S. FDA in April 2020 for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. According to data from the pivotal Phase 3 ASCENT trial, treatment with sacituzumab govitecan-hziy reduced the risk of death by 52% (p <0.0001), reduced the risk of disease progression by 59% (p <0.0001) and increased median overall survival (12.1 vs. 6.7 months) compared with chemotherapy. Under a licensing agreement with Gilead Sciences, Inc., Everest Medicines has exclusive rights to develop, register, and commercialize sacituzumab govitecan-hziy for all cancer indications in Greater China, South Korea, and certain Southeast Asian countries.
In October 2020, sacituzumab govitecan-hziy was included in the updated 2020 China Guidelines for the Standardized Diagnosis and Treatment of Advanced Breast Cancer, compiled by the Breast Cancer Expert Committee of the National Cancer Control Center, the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association, and the Cancer Drug Clinical Research Professional Committee of the Chinese Anti-Cancer Association.
About Triple-Negative Breast Cancer
Triple-Negative Breast Cancer (TNBC) is a highly aggressive disease and accounts for approximately 15-20% of all breast cancer types worldwide.i-iii The median age of breast cancer diagnoses tends to be younger in China than western countries, and the percentage of the TNBC molecular subtype has been increasing in the past 10 years. TNBC cells lack sufficient estrogen, progesterone or HER2 receptor expression to benefit from the use of hormonal or HER2-directed therapy. Overall survival among patients with this form of breast cancer has not changed in the past 20 years, which highlights the need for advances in therapeutic options for these patients.iv-viii